Milestone Q2 net loss widens to $28.6 million as CARDAMYST sales begin
Milestone Pharmaceuticals reported second-quarter 2026 results with first product revenue of $559,000 for CARDAMYST, which launched in mid-February 2026. The net loss widened to $28.6 million, or $0.21 per share, from $13.0 million, or $0.20 per share, a year earlier, driven by higher selling, general and administrative expense tied to the launch. The company said its $170.6 million in cash and short-term investments is expected to fund operations into the second half of 2027.
Key points
- Q2 2026 product revenue was $559,000, compared with none in Q2 2025; six-month product revenue was $797,000.
- Q2 2026 net loss was $28.6 million, or $0.21 per share, versus $13.0 million, or $0.20 per share, in Q2 2025.
- Selling, general and administrative expense rose to $22.6 million from $8.9 million, which the company attributed to CARDAMYST launch costs.
- Cash, cash equivalents and short-term investments were $170.6 million at June 30, 2026, versus $106.0 million at December 31, 2025.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.